Integra earnings beat by $0.03, revenue fell short of estimates

Integra (IART) reported Q3 EPS of $0.59, beating estimates by $0.03, but revenue of $411.2M missed expectations. Guidance for Q4 and FY 2026 was below consensus. The stock is down 40.17% over the last 3 months.

Original reporting
Published Oct 21, 2026, 8:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IART
Bearish
high confidence
Mentioned
$IART
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IARTBearishMed
01

Why it matters

Traders will likely focus on the guidance gap versus consensus because it directly affects forward earnings estimates and valuation multiples.

02

Market read

Fresh earnings and guidance numbers create an immediate repricing window for IART’s near-term expectations.

03

What to watch

The article does not include segment performance, backlog, or margin details, so the guidance miss may be driven by factors not captured here (timing, mix, or one-offs).

Relevance 8/10Novelty 8/10Timing: post-earnings, after-hours/next-session positioning based on fresh Q3 results and Q4/FY guidance

Background

This is a reported Q3 earnings beat with revenue shortfall, followed by Q4 and FY guidance that trails analyst consensus.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra (IART) reported Q3 EPS of $0.59, beating estimates by $0.03, but revenue missed at $411.2M vs $414.25M, and issued weaker Q4/FY guidance.

Expected impact

Likely downward pressure as the market reprices Q4 and FY earnings power after guidance under consensus.

Evidence & confidence

The article provides both the earnings print (EPS beat, revenue miss) and explicit Q4 and FY guidance ranges that are below analyst consensus for EPS and revenue.

Market effects

Limited sector read-through since this is a single-company earnings and guidance update.

No direct regional spillover beyond typical tech/earnings sentiment effects mentioned in the opening market wrap.

Primarily company-specific; no global macro or cross-border catalyst in the provided text.

Counterpoint

The EPS beat could still support the stock if investors focus on cost discipline or margin resilience, treating the revenue miss as temporary.

Key entities

  • Integra

    Reported Q3 EPS and revenue versus consensus and provided Q4 and FY 2026 guidance ranges.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.